ValuEngine upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a sell rating to a hold rating in a research report report published on Thursday morning.
MDSO has been the subject of several other reports. Morgan Stanley lowered their target price on Medidata Solutions from $86.00 to $79.00 and set an overweight rating for the company in a research note on Friday, February 9th. TheStreet upgraded Medidata Solutions from a c+ rating to a b- rating in a research note on Monday, March 12th. Zacks Investment Research downgraded Medidata Solutions from a hold rating to a sell rating in a research note on Thursday. BidaskClub upgraded Medidata Solutions from a sell rating to a hold rating in a research note on Tuesday, January 16th. Finally, Needham & Company LLC lowered their target price on Medidata Solutions to $75.00 and set a buy rating for the company in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $82.07.
Shares of Medidata Solutions stock opened at $66.44 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.49 and a quick ratio of 1.49. The stock has a market cap of $3,953.82, a PE ratio of 78.16, a price-to-earnings-growth ratio of 3.51 and a beta of 1.53. Medidata Solutions has a 1-year low of $59.22 and a 1-year high of $85.92.
In other Medidata Solutions news, CEO Tarek Sherif sold 26,836 shares of the firm’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $70.25, for a total value of $1,885,229.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $66.46, for a total transaction of $132,920.00. Following the completion of the transaction, the chief financial officer now directly owns 87,775 shares in the company, valued at approximately $5,833,526.50. The disclosure for this sale can be found here. Insiders have sold 35,836 shares of company stock worth $2,495,689 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of MDSO. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Medidata Solutions by 48.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock worth $205,000 after acquiring an additional 1,056 shares during the last quarter. Meadow Creek Investment Management LLC lifted its holdings in Medidata Solutions by 31.4% in the fourth quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock worth $233,000 after acquiring an additional 880 shares during the last quarter. Polen Capital Management LLC lifted its holdings in Medidata Solutions by 77.0% in the fourth quarter. Polen Capital Management LLC now owns 4,640 shares of the company’s stock worth $294,000 after acquiring an additional 2,018 shares during the last quarter. Brown Advisory Securities LLC bought a new position in Medidata Solutions in the fourth quarter worth about $356,000. Finally, Elkfork Partners LLC bought a new position in Medidata Solutions in the fourth quarter worth about $408,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://weekherald.com/2018/04/16/medidata-solutions-mdso-stock-rating-upgraded-by-valuengine.html.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.